lenalidomide,idecabtagene vicleucel
bms,2seventy bio
['mmsm', 'multiple myeloma', 'karmma', 'karmma-2', 'idecabtagene']
. shows karmma-2 cohort 2a results for car-t with an overall response of 83.8% and median duration of response of 15.7 months, demonstrating deep and frequent responses in patients with high-risk myeloma #ash22 #mmsm 
Supporting, educating and connecting myeloma patients and their loved ones while actively seeking a cure. #myeloma #mmsm #hematology #multiplemyeloma